Home / Intelligence / White Papers / Predicting Winners: AI-Powered Portfolio Management
Can artificial intelligence and machine learning (AIML) be used to support portfolio decision-making across the life sciences industry?
In this installment of our Industry Impact Series, we find that not only can the latest AIML techniques identify the drivers of success and failure in commercialization, but Trinity Life Sciences’ AI algorithm accurately predicts revenue outcomes for >90% of U.S. drug launches, far exceeding the accuracy of Wall Street analyst consensus at the time of launch (<60%).
Trinity’s AI algorithm incorporates publicly available and Trinity-proprietary data from our Annual Drug Index on 250+ U.S. drug launches since 2014. Read our white paper, Predicting Winners: AI-Powered Portfolio Management, to learn more.
In Case You Missed It
Complete the form below to access the full white paper
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Webinars
Launch & Learn: Trinity Launch Accelerator
Available On Demand
Today’s launch environment is fraught with greater complexity, lack of standardization and executional inefficiency. Join us for a virtual lunch and learn where experts share how Launch Accelerator enables teams to overcome launch barriers with a simple launch readiness and management process.
Watch Now
Webinars
Trinity Annual Drug Index
Available On Demand
White Paper & On-demand Webinar: This report, the seventh in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the performance of novel drugs approved by the FDA in 2021, scoring each […]
Watch Now
Webinars
Navigating the Early Asset Evaluation Journey with Confidence
Available On Demand
There is no room for missteps along the journey to evaluate the viability of assets in early stages of development. When making go/no go decisions, many critical questions must be answered across the early asset lifecycle. Join a team of cross-functional experts for a lively panel discussion on how to approach early commercial assessment with insight from various perspectives.
Watch Now